Price movement over the last 24 hours
Abeona Therapeutics Inc vs eBay Inc — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while eBay Inc trades at $114.45 (market cap $50.94B). The key difference: eBay Inc is far larger — about 136.5× Abeona Therapeutics Inc's market cap, and eBay Inc pays a 1.08% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | EBAY | |
|---|---|---|
Market Cap | $373.32M | $50.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $118.96 |
52-Week Low | $4.17 | $75.33 |
Enterprise Value | $228.22M | $54.28B |
Volume | — | 5,186,418 |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EBAY trades at $114.71, down slightly by 0.11% today. The stock shows strong profitability with a 17.61% net income margin and has beaten earnings estimates for three consecutive quarters. Technical indicators are bullish, with the price above key moving averages. Recent news highlights GameStop's unsolicited takeover interest, adding speculative momentum. Cash flow turned negative in 2025 but is projected to recover in 2026.
The outlook is mixed: solid fundamentals and earnings beats support upside, but the stock trades above the analyst consensus target of $109.50. Risks include takeover uncertainty and competitive pressures. Wall Street sentiment is neutral with a slight buy bias, though valuation multiples like P/E of 26.25 suggest limited near-term growth potential.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →